ArticleJournal for immunotherapy of cancer2025

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.

Yingqi Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.